메뉴 건너뛰기




Volumn 16, Issue 4, 2009, Pages 9-21

Optimizing the management of advanced non-small-cell lung cancer: A personal view

Author keywords

Advanced non small cell lung cancer; Personal view; Treatment

Indexed keywords

APREPITANT; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; ERLOTINIB; ETOPOSIDE; GEFITINIB; GEMCITABINE; K RAS PROTEIN; MITOMYCIN; NAVELBINE; PACLITAXEL; PEMETREXED; PLACEBO; VINBLASTINE; ZOLEDRONIC ACID;

EID: 70350578566     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.v16i4.465     Document Type: Review
Times cited : (16)

References (69)
  • 1
    • 15744373791 scopus 로고    scopus 로고
    • Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC, eds. World Health Organization Classification of Tumours 7. Lyon, France: IARC Press
    • Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC, eds. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. World Health Organization Classification of Tumours 7. Lyon, France: IARC Press; 2004.
    • (2004) Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart
  • 2
    • 62249156223 scopus 로고    scopus 로고
    • Morphologic features of adenocarcinoma of the lung predictive of response to the epidermal growth factor receptor kinase inhibitors erlotinib and gefitinib
    • Zakowski MF, Hussain S, Pao W, et al. Morphologic features of adenocarcinoma of the lung predictive of response to the epidermal growth factor receptor kinase inhibitors erlotinib and gefitinib. Arch Pathol Lab Med 2009;133:470-477
    • (2009) Arch Pathol Lab Med , vol.133 , pp. 470-477
    • Zakowski, M.F.1    Hussain, S.2    Pao, W.3
  • 3
    • 15744372810 scopus 로고    scopus 로고
    • KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib
    • Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005;2:e17.
    • (2005) PLoS Med , vol.2
    • Pao, W.1    Wang, T.Y.2    Riely, G.J.3
  • 4
    • 52049090365 scopus 로고    scopus 로고
    • Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21
    • Zhu CQ, da Cunha Santos G, Ding K, et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008;26:4268-4275
    • (2008) J Clin Oncol , vol.26 , pp. 4268-4275
    • Zhu, C.Q.1    Da Cunha Santos, G.2    Ding, K.3
  • 7
    • 36749103137 scopus 로고    scopus 로고
    • Auf dem Weg zu einer individualisierten Therapie des nicht-kleinzelligen Bronchialkarzinoms (NSCLC) - Stellenwert molekularer pradiktions- und prognosefaktoren
    • DOI 10.1055/s-2007-980130
    • Zirlik S, Lampert S, Hahn EG, Wiest GH, Bruckl WM. An approach to individualized therapy of non-small cell lung carcinoma (NSCLC) - relevance of molecular predictive and prognostic factors [German]. Pneumologie 2007;61:731-738 (Pubitemid 350214159)
    • (2007) Pneumologie , vol.61 , Issue.11 , pp. 731-740
    • Zirlik, S.1    Lampert, S.2    Hahn, E.G.3    Wiest, G.H.4    Bruckl, W.M.5
  • 8
    • 34250843259 scopus 로고    scopus 로고
    • Weighing tumor biology in treatment decisions for patients with non-small cell lung cancer
    • DOI 10.1097/01.JTO.0000269737.05962.a0, PII 0124389420070600200004
    • Shepherd FA, Rosell R. Weighing tumor biology in treatment decisions for patients with non-small cell lung cancer. J Thorac Oncol 2007;2(suppl 2):S68-76. (Pubitemid 46988096)
    • (2007) Journal of Thoracic Oncology , vol.2 , Issue.SUPPL. 2
    • Shepherd, F.A.1    Rosell, R.2
  • 9
    • 63349108087 scopus 로고    scopus 로고
    • Value and limitations of measuring HER-2 extracellular domain in the serum of breast cancer patients
    • Leary AF, Hanna WM, van de Vijver MJ, et al. Value and limitations of measuring HER-2 extracellular domain in the serum of breast cancer patients. J Clin Oncol 2009;27:1694-1705
    • (2009) J Clin Oncol , vol.27 , pp. 1694-1705
    • Leary, A.F.1    Hanna, W.M.2    Van De Vijver, M.J.3
  • 14
    • 37349108995 scopus 로고    scopus 로고
    • Pemetrexed + carboplatin versus gemcitabine + carboplatin in the treatment of stage IIIB/IV non-small cell lung cancer
    • abstract 7517. Available online at: cited June 26, 2009
    • Grønberg BH, Bremnes R, Aasebø U, et al. Pemetrexed + carboplatin versus gemcitabine + carboplatin in the treatment of stage IIIB/IV non-small cell lung cancer [abstract 7517]. Proc Am Soc Clin Oncol 2007;25:. [Available online at: www.asco. org/ASCOv2/Meetings/Abstracts?&vmview=abst- detail-view &confID=47&abstractID=31787; cited June 26, 2009]
    • (2007) Proc Am Soc Clin Oncol , vol.25
    • Grønberg, B.H.1    Bremnes, R.2    Aasebø, U.3
  • 15
    • 49049089802 scopus 로고    scopus 로고
    • Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advanced-stage non-small-cell lung cancer
    • Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26:3543-3551
    • (2008) J Clin Oncol , vol.26 , pp. 3543-3551
    • Scagliotti, G.V.1    Parikh, P.2    Von Pawel, J.3
  • 16
    • 24944497744 scopus 로고    scopus 로고
    • Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib
    • Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005;23:5900-5909
    • (2005) J Clin Oncol , vol.23 , pp. 5900-5909
    • Eberhard, D.A.1    Johnson, B.E.2    Amler, L.C.3
  • 17
    • 45149102984 scopus 로고    scopus 로고
    • Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023
    • Kelly K, Chansky K, Gaspar LE, et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol 2008;26:2450-2456
    • (2008) J Clin Oncol , vol.26 , pp. 2450-2456
    • Kelly, K.1    Chansky, K.2    Gaspar, L.E.3
  • 18
    • 52749099497 scopus 로고    scopus 로고
    • Assessment of somatic K-ras mutations as a mechanism associated with resistance to EGFR-targeted agents: A systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer
    • Linardou H, Dahabreh IJ, Kanaloupiti D, et al. Assessment of somatic K-ras mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 2008;9:962-972
    • (2008) Lancet Oncol , vol.9 , pp. 962-972
    • Linardou, H.1    Dahabreh, I.J.2    Kanaloupiti, D.3
  • 20
    • 0028843552 scopus 로고
    • Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials
    • Non-Small Cell Lung Cancer Collaborative Group
    • Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 1995;311:899-909.
    • (1995) Br Med J , vol.311 , pp. 899-909
  • 21
    • 0022646219 scopus 로고
    • Long-term survivors in metastatic non-small-cell lung cancer: An Eastern Cooperative Oncology Group study
    • Finkelstein DM, Ettinger DS, Ruckdeschel JC. Long-term survivors in metastatic non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study. J Clin Oncol 1986; 4:702-709 (Pubitemid 16114717)
    • (1986) Journal of Clinical Oncology , vol.4 , Issue.5 , pp. 702-709
    • Finkelstein, D.M.1    Ettinger, D.S.2    Ruckdeschel, J.C.3
  • 22
    • 0033950286 scopus 로고    scopus 로고
    • Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an Eastern Cooperative Oncology Group trial
    • Bonomi P, Kim K, Fairclough D, et al. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 2000;18:623-631
    • (2000) J Clin Oncol , vol.18 , pp. 623-631
    • Bonomi, P.1    Kim, K.2    Fairclough, D.3
  • 26
    • 33144474858 scopus 로고    scopus 로고
    • Should chemotherapy combinations for advanced non-small cell lung cancer be platinum-based? a meta-analysis of phase III randomized trials
    • DOI 10.1016/j.lungcan.2005.11.001, PII S0169500205005830
    • Pujol JL, Barlesi F, Daurès JP. Should chemotherapy combinations for advanced non-small cell lung cancer be platinumbased? A meta-analysis of phase III randomized trials. Lung Cancer 2006;51:335-345 (Pubitemid 43265817)
    • (2006) Lung Cancer , vol.51 , Issue.3 , pp. 335-345
    • Pujol, J.-L.1    Barlesi, F.2    Daures, J.-P.3
  • 27
    • 10444237218 scopus 로고    scopus 로고
    • Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: A meta-analysis of survival outcomes
    • Le Chevalier T, Scagliotti G, Natale R, et al. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer 2005;47:69-80.
    • (2005) Lung Cancer , vol.47 , pp. 69-80
    • Le Chevalier, T.1    Scagliotti, G.2    Natale, R.3
  • 29
    • 44949218458 scopus 로고    scopus 로고
    • Second or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced disease
    • CD004569
    • Delbaldo C, Michiels S, Rolland E, et al. Second or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced disease. Cochrane Database Syst Rev 2007;(4):CD004569.
    • (2007) Cochrane Database Syst Rev , Issue.4
    • Delbaldo, C.1    Michiels, S.2    Rolland, E.3
  • 30
    • 34347379142 scopus 로고    scopus 로고
    • Cisplatin- versus carboplatin- based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: An individual patient data metaanalysis
    • Ardizzoni A, Boni L, Tiseo M, et al. Cisplatin- versus carboplatin- based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data metaanalysis. J Natl Cancer Inst 2007;99:847-857
    • (2007) J Natl Cancer Inst , vol.99 , pp. 847-857
    • Ardizzoni, A.1    Boni, L.2    Tiseo, M.3
  • 31
    • 60149111149 scopus 로고    scopus 로고
    • Optimal duration of first-line chemotherapy for advanced non-small cell lung cancer: A systematic review with meta-analysis
    • Lima JP, dos Santos LV, Sasse EC, Sasse AD. Optimal duration of first-line chemotherapy for advanced non-small cell lung cancer: a systematic review with meta-analysis. Eur J Cancer 2009;45:601-607
    • (2009) Eur J Cancer , vol.45 , pp. 601-607
    • Lima, J.P.1    Dos Santos, L.V.2    Sasse, E.C.3    Sasse, A.D.4
  • 32
    • 0035281498 scopus 로고    scopus 로고
    • Duration of chemotherapy in advanced non-small-cell lung cancer: A randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin
    • Smith IE, O'Brien ME, Talbot DC, et al. Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol 2001;19:1336-1343
    • (2001) J Clin Oncol , vol.19 , pp. 1336-1343
    • Smith, I.E.1    O'Brien, M.E.2    Talbot, D.C.3
  • 35
    • 2442661845 scopus 로고    scopus 로고
    • Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy
    • Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-1597
    • (2004) J Clin Oncol , vol.22 , pp. 1589-1597
    • Hanna, N.1    Shepherd, F.A.2    Fossella, F.V.3
  • 36
    • 64049105491 scopus 로고    scopus 로고
    • Is pemetrexed more effective in adenocarcinoma and large cell lung cancer than in squamous cell carcinoma? A retrospective analysis of a phase III trial of pemetrexed vs docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC)
    • Peterson P, Park K, Fossella F, Gatzemeier U, John W, Scagliotti G. Is pemetrexed more effective in adenocarcinoma and large cell lung cancer than in squamous cell carcinoma? A retrospective analysis of a phase III trial of pemetrexed vs docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC). J Thorac Oncol 2007;2(suppl 4):S316-17.
    • (2007) J Thorac Oncol , vol.2 , Issue.SUPPL. 4
    • Peterson, P.1    Park, K.2    Fossella, F.3    Gatzemeier, U.4    John, W.5    Scagliotti, G.6
  • 37
    • 64049115311 scopus 로고    scopus 로고
    • The differential efficacy of pemetrexed according to NSCLC histology: A review of two phase III studies
    • Scagliotti G, Hanna N, Fossella F, et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies. Oncologist 2009;14:253-263
    • (2009) Oncologist , vol.14 , pp. 253-263
    • Scagliotti, G.1    Hanna, N.2    Fossella, F.3
  • 38
    • 33749077728 scopus 로고    scopus 로고
    • Elderly patients benefit from second-line cytotoxic chemotherapy: A subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer
    • DOI 10.1200/JCO.2006.06.7835
    • Weiss GJ, Langer C, Rosell R, et al. Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small- cell lung cancer. J Clin Oncol 2006;24:4405-4413 (Pubitemid 46630978)
    • (2006) Journal of Clinical Oncology , vol.24 , Issue.27 , pp. 4405-4411
    • Weiss, G.J.1    Langer, C.2    Rosell, R.3    Hanna, N.4    Shepherd, F.5    Einhorn, L.H.6    Nguyen, B.7    Paul, S.8    McAndrews, P.9    Bunn Jr., P.A.10    Kelly, K.11
  • 39
    • 37549036328 scopus 로고    scopus 로고
    • Lung Cancer Symptom Scale outcomes in relation to standard efficacy measures: An analysis of the phase III study of pemetrexed versus docetaxel in advanced non-small cell lung cancer
    • de Marinis F, Pereira JR, Fossella F, et al. Lung Cancer Symptom Scale outcomes in relation to standard efficacy measures: an analysis of the phase III study of pemetrexed versus docetaxel in advanced non-small cell lung cancer. J Thorac Oncol 2008;3:30-36
    • (2008) J Thorac Oncol , vol.3 , pp. 30-36
    • De Marinis, F.1    Pereira, J.R.2    Fossella, F.3
  • 40
    • 22044445517 scopus 로고    scopus 로고
    • Erlotinib in previously treated non-small-cell lung cancer
    • Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-132
    • (2005) N Engl J Med , vol.353 , pp. 123-132
    • Shepherd, F.A.1    Rodrigues Pereira, J.2    Ciuleanu, T.3
  • 41
    • 22044453790 scopus 로고    scopus 로고
    • Erlotinib in lung cancer - Molecular and clinical predictors of outcome
    • Erratum in: N Engl J Med 2006;355:1746
    • Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 2005;353:133-44. [Erratum in: N Engl J Med 2006;355:1746]
    • (2005) N Engl J Med , vol.353 , pp. 133-144
    • Tsao, M.S.1    Sakurada, A.2    Cutz, J.C.3
  • 42
    • 33745928129 scopus 로고    scopus 로고
    • Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group Study br.21
    • Clark GM, Zborowski DM, Santabarbara P, et al. Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21. Clin Lung Cancer 2006;7:389-394 (Pubitemid 44043548)
    • (2006) Clinical Lung Cancer , vol.7 , Issue.6 , pp. 389-394
    • Clark, G.M.1    Zborowski, D.M.2    Santabarbara, P.3    Ding, K.4    Whitehead, M.5    Seymour, L.6    Shepherd, F.A.7
  • 43
    • 27544503230 scopus 로고    scopus 로고
    • Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
    • DOI 10.1016/S0140-6736(05)67625-8, PII S0140673605676258
    • Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366:1527-1537 (Pubitemid 41540110)
    • (2005) Lancet , vol.366 , Issue.9496 , pp. 1527-1537
    • Thatcher, N.1    Chang, A.2    Parikh, P.3    Pereira, J.R.4    Ciuleanu, T.5    Von Pawel, J.6    Thongprasert, S.7    Tan, E.H.8    Pemberton, K.9    Archer, V.10    Carroll, K.11
  • 44
    • 56249109644 scopus 로고    scopus 로고
    • Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): A randomised phase III trial
    • Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008;372:1809-1818
    • (2008) Lancet , vol.372 , pp. 1809-1818
    • Kim, E.S.1    Hirsh, V.2    Mok, T.3
  • 45
    • 59749100191 scopus 로고    scopus 로고
    • Phase III, randomized, open-label, first-line study of gefitinib (G) vs carboplatin/paclitaxel (C/P) in clinically selected patients (Pts) with advanced non-small-cell lung cancer (NSCLC) (IPASS)
    • abstract LBA2
    • Mok T, Wu YL, Thongprasert S, et al. Phase III, randomized, open-label, first-line study of gefitinib (G) vs carboplatin/paclitaxel (C/P) in clinically selected patients (Pts) with advanced non-small-cell lung cancer (NSCLC) (IPASS) [abstract LBA2]. Ann Oncol 2008;19(suppl 8): viii1-viii4.
    • (2008) Ann Oncol , vol.19 , Issue.SUPPL. 8
    • Mok, T.1    Wu, Y.L.2    Thongprasert, S.3
  • 46
    • 62449124416 scopus 로고    scopus 로고
    • Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL
    • Erratum in: J Clin Oncol 2009;27:2415
    • Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. J Clin Oncol 2009;27:1227-34. [Erratum in: J Clin Oncol 2009;27:2415]
    • (2009) J Clin Oncol , vol.27 , pp. 1227-1234
    • Reck, M.1    Von Pawel, J.2    Zatloukal, P.3
  • 48
    • 65349091355 scopus 로고    scopus 로고
    • Randomized phase ii and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer
    • Smit EF, Burgers SA, Biesma B, et al. Randomized phase ii and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer. J Clin Oncol 2009;27:2038-2045
    • (2009) J Clin Oncol , vol.27 , pp. 2038-2045
    • Smit, E.F.1    Burgers, S.A.2    Biesma, B.3
  • 49
    • 0023851771 scopus 로고
    • First-line chemotherapy rechallenge after relapse in small cell lung cancer
    • Vincent M, Evans B, Smith I. First-line chemotherapy rechallenge after relapse in small cell lung cancer. Cancer Chemother Pharmacol 1988;21:45-48 (Pubitemid 18050480)
    • (1988) Cancer Chemotherapy and Pharmacology , vol.21 , Issue.1 , pp. 45-48
    • Vincent, M.1    Evans, B.2    Smith, I.3
  • 50
    • 67650281462 scopus 로고    scopus 로고
    • Phase III study by the Norwegian Lung Cancer Study Group: Pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer
    • Epub ahead of print
    • Grønberg BH, Bremnes RM, Fløtten O, et al. Phase III study by the Norwegian Lung Cancer Study Group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2009;[Epub ahead of print].
    • (2009) J Clin Oncol
    • Grønberg, B.H.1    Bremnes, R.M.2    Fløtten, O.3
  • 51
    • 51349109631 scopus 로고    scopus 로고
    • FLEX: A randomized, multicenter, phase II study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC)
    • abstract 3. Available online at: cited June 26, 2009
    • Pirker R, Szczesna A, von Pawel J, et al. FLEX: a randomized, multicenter, phase II study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) [abstract 3]. Proc Am Soc Clin Oncol 2008:26:6S. [Available online at: www.asco.org/ASCOv2/Meetings/ Abstracts?&vmview=abst-detail-view&confID=55&abstractID=30338; cited June 26, 2009]
    • (2008) Proc Am Soc Clin Oncol , vol.26
    • Pirker, R.1    Szczesna, A.2    Von Pawel, J.3
  • 53
    • 0035281498 scopus 로고    scopus 로고
    • Duration of chemotherapy in advanced non-small-cell lung cancer: A randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin
    • Smith IE, O'Brien ME, Talbot DC, et al. Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol 2001;19:1336-1343
    • (2001) J Clin Oncol , vol.19 , pp. 1336-1343
    • Smith, I.E.1    O'Brien, M.E.2    Talbot, D.C.3
  • 57
    • 33646485007 scopus 로고    scopus 로고
    • Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trial
    • Brodowicz T, Krzakowski M, Zwitter M, et al. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer 2006;52:155-163
    • (2006) Lung Cancer , vol.52 , pp. 155-163
    • Brodowicz, T.1    Krzakowski, M.2    Zwitter, M.3
  • 58
    • 59149092945 scopus 로고    scopus 로고
    • Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer
    • Fidias PM, Dakhil SR, Lyss AP, et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2009;27:591-598
    • (2009) J Clin Oncol , vol.27 , pp. 591-598
    • Fidias, P.M.1    Dakhil, S.R.2    Lyss, A.P.3
  • 59
    • 70349092474 scopus 로고    scopus 로고
    • Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: A randomized phase III study in advanced non-small cell lung cancer (NSCLC)
    • abstract CRA8000. Available online at: cited June 26, 2009
    • Belani CP, Brodowicz T, Ciuleanu T, et al. Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: a randomized phase III study in advanced non-small cell lung cancer (NSCLC) [abstract CRA8000]. Proc Am Soc Clin Oncol 2009;27:. [Available online at: www.asco.org/ ASCOv2/Meetings/Abstracts?&vmview=abst-detail-view& confID= 65&abstractID=33019; cited June 26, 2009]
    • (2009) Proc Am Soc Clin Oncol , vol.27
    • Belani, C.P.1    Brodowicz, T.2    Ciuleanu, T.3
  • 60
    • 70349475409 scopus 로고    scopus 로고
    • SATURN: A double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC
    • abstract 8001. Available online at: cited June 26, 2009
    • Cappuzzo F, Ciuleanu T, Stelmakh L, et al. SATURN: a double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC [abstract 8001]. Proc Am Soc Clin Oncol 2009;27:. [Available online at: www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst-detail- view&confID=65&abstractID=32756; cited June 26, 2009]
    • (2009) Proc Am Soc Clin Oncol , vol.27
    • Cappuzzo, F.1    Ciuleanu, T.2    Stelmakh, L.3
  • 61
    • 70349476965 scopus 로고    scopus 로고
    • Biomarker analyses from the phase III placebo-controlled SATURN study of maintenance erlotinib following first-line chemotherapy for advanced NSCLC
    • abstract 8020. Available online at: cited June 26, 2009
    • Brugger W, Triller N, Blasinska-Morawiec M, et al. Biomarker analyses from the phase III placebo-controlled SATURN study of maintenance erlotinib following first-line chemotherapy for advanced NSCLC [abstract 8020]. Proc Am Soc Clin Oncol 2009;27:. [Available online at: www.asco.org/ASCOv2/ Meetings/Abstracts?&vmview=abst-detail-view&confID= 65&abstractID= 32849; cited June 26, 2009]
    • (2009) Proc Am Soc Clin Oncol , vol.27
    • Brugger, W.1    Triller, N.2    Blasinska-Morawiec, M.3
  • 62
    • 70349477817 scopus 로고    scopus 로고
    • A randomized, double-blind, placebo-controlled, phase IIIB trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC)
    • on behalf of the ATLAS Investigators. abstract LBA8002. Available online at: cited June 26, 2009
    • Miller VA, O'Connor P, Soh C, Kabbinavar F, on behalf of the ATLAS Investigators. A randomized, double-blind, placebo-controlled, phase IIIB trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC) [abstract LBA8002]. Proc Am Soc Clin Oncol 2009;27:. [Available online at: www.asco.org/ASCOv2/ Meetings/ Abstracts?&vmview=abst-detail-view&confID=65&abstract ID=30819; cited June 26, 2009]
    • (2009) Proc Am Soc Clin Oncol , vol.27
    • Miller, V.A.1    O'Connor, P.2    Soh, C.3    Kabbinavar, F.4
  • 63
    • 70350609719 scopus 로고    scopus 로고
    • Cisplatin in non-small cell lung cancer (NSCLC) - Reducing the most prominent toxicity, emesis: Results of a meta-analysis with 1527 patients in randomized clinical trials (RCTS) testing the addition of an NK1 antagonist
    • abstract 8064. Available online at: cited June 26, 2009
    • Gralla RJ, Raftopoulos H, Bria E, Hesketh PJ. Cisplatin in non-small cell lung cancer (NSCLC) - reducing the most prominent toxicity, emesis: results of a meta-analysis with 1527 patients in randomized clinical trials (RCTS) testing the addition of an NK1 antagonist [abstract 8064]. Proc Am Soc Clin Oncol 2008;26:. [Available online at: www.asco.org/ASCOv2/Meetings/ Abstracts?&vmview=abst-detail-view&confID=55&abstract ID=34689; cited June 26, 2009]
    • (2008) Proc Am Soc Clin Oncol , vol.26
    • Gralla, R.J.1    Raftopoulos, H.2    Bria, E.3    Hesketh, P.J.4
  • 64
    • 43249128301 scopus 로고    scopus 로고
    • Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity
    • DOI 10.1097/JTO.0b013e3181651c0e, PII 0124389420080300000006
    • Hirsh V, Major PP, Lipton A, et al. Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity. J Thorac Oncol 2008;3:228-236 (Pubitemid 351654321)
    • (2008) Journal of Thoracic Oncology , vol.3 , Issue.3 , pp. 228-236
    • Hirsh, V.1    Major, P.P.2    Lipton, A.3    Cook, R.J.4    Langer, C.J.5    Smith, M.R.6    Brown, J.E.7    Coleman, R.E.8
  • 67
    • 52949124117 scopus 로고    scopus 로고
    • Parenteral anticoagulation may prolong the survival of patients with limited small cell lung cancer: A Cochrane systematic review
    • Akl EA, van Doormaal FF, Barba M, et al. Parenteral anticoagulation may prolong the survival of patients with limited small cell lung cancer: a Cochrane systematic review. J Exp Clin Cancer Res 2008;27:4.
    • (2008) J Exp Clin Cancer Res , vol.27 , pp. 4
    • Akl, E.A.1    Van Doormaal, F.F.2    Barba, M.3
  • 68
    • 53249145767 scopus 로고    scopus 로고
    • Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma
    • Riely GJ, Kris MG, Rosenbaum D, et al. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res 2008;14:5731-5734
    • (2008) Clin Cancer Res , vol.14 , pp. 5731-5734
    • Riely, G.J.1    Kris, M.G.2    Rosenbaum, D.3
  • 69
    • 62449241907 scopus 로고    scopus 로고
    • Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers
    • Hughes AN, O'Brien ME, Petty WJ, et al. Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers. J Clin Oncol 2009;27:1220-1226
    • (2009) J Clin Oncol , vol.27 , pp. 1220-1226
    • Hughes, A.N.1    O'Brien, M.E.2    Petty, W.J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.